Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region

A Prospective, Multicenter Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07566286

Enrollment

100

Registered

2026-05-05

Start date

2026-06-03

Completion date

2028-02-28

Last updated

2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chin Augmentation

Brief summary

The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.

Interventions

DEVICERestylane Lyft with Lidocaine

Sterile gel of hyaluronic acid.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

22 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older. 2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Exclusion criteria

1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins. 2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics. 3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions. 4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale. 5. Any previous aesthetic procedures or implants. 6. Presence of any disease or lesions near or on the area to be treated.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Device And/Or Injection Procedure After the Month 12 Optional Retreatment	From Month 12 up to 3 months after optional retreatment (i.e. Month 15)	An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational product (IP). TEAEs that are related to the device and/or injection procedure after the Month 12 optional retreatment will be reported.

Countries

United States

Contacts

CONTACTClinical Project Manager

clinical.studies@galderma.com817-961-5000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026